Merck Animal Health today announced the completion of its previously announced acquisition of the US rights to SENTINEL FLAVOR TABS and SENTINEL SPECTRUM Chews in the companion animal category from Virbac.
Comprehensive parasite protection is an essential part of canine overall health and well-being. “Our veterinary medicines, including parasiticides and vaccines continue to transform the animal health industry and further solidify our position in the US Companion Animal category,” said Rick DeLuca, President, Merck Animal Health. “The extensive breadth and depth of our product portfolio enhances our offerings of comprehensive pet care solutions, which provide a full range of complementary solutions for our customers to improve the health and well-being of animals and the people who care for them.”
Virbac offers veterinarians, farmers and pet owners in more than 100 countries a practical range of products and services for diagnosing, preventing and treating the majority of diseases while improving quality of life for animals. “Under the terms of this agreement, Virbac will divest a combination of titles and rights for the United States on trademarks, marketing authorizations, patents, know-how and other assets, related to two parasiticides for dogs: SENTINEL FLAVOR TABS and SENTINEL SPECTRUM,” said a statement on Virbac’s website. “In relation with the transaction, Virbac will keep its commercial structure substantially unchanged and will continue to manufacture SENTINEL SPECTRUM at its Bridgeton, Missouri site for the next 10 years.”